{"classes":[{"categories":[{"measurements":[{"comment":"An upper limit for the 95% Confidence Interval was unable to be reached due for OS to ongoing survival in some HR-MDS patients at the time of cutoff for data analysis (i.e., \\~21 months).","groupId":"OG000","lowerLimit":"8.5","upperLimit":"NA","value":"9.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Median OS is reported in patients with HR-MDS at the time of censoring of data for the Primary Outcome analysis. For purposes of this study, OS refers to the duration of time from treatment initiation until a patient's death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Administration: Decitabine is reconstituted with 5 ml sterile water to facilitate subcutaneous administration. Decitabine is given by subcutaneous injection. Venetoclax is taken as a tablet prepared by patients pharmacy. Venetoclax is given at a dose of 400 mg po once per week concurrently with the Decitabine dose (+/- 1 day allowed ).\n\nVenetoclax: Venetoclax 400 mg po on days 1, 8, 15 and 22 of each cycle (28-day cycle)\n\nDecitabine: Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)","id":"OG000","title":"Decitabine/Venetoclax (Single Arm)"}],"paramType":"MEDIAN","populationDescription":"6 patients who comprised the Primary Outcome analysis were part of the HR-MDS cohort.","reportingStatus":"POSTED","timeFrame":"At the time of censoring of data, up to ~21 months","title":"Overall Survival in HR-MDS Patients","type":"POST_HOC","unitOfMeasure":"months"}